Seale L, Jones C J, Kathpalia S, Jackson G G, Mozes M, Maddux M S, Packham D
JAMA. 1985 Dec 27;254(24):3435-8.
Forty patients with serum antibody against herpes simplex virus (HSV) were enrolled in a randomized, placebo-controlled, double-blind investigation of acyclovir given orally in a low dosage as prophylaxis against recurrent HSV infection after renal transplantation. During 30 postoperative days of medication, 14 of 21 placebo-treated and one of 19 acyclovir-treated patient(s) developed reactivation of HSV infection. Eleven of the former, but not the latter, had herpetic lesions. The protection against active infection with HSV during the period of prophylaxis with acyclovir is statistically highly significant. From 30 to 90 days after transplantation when no antiviral medicine was given, 60% (3/5) of the remaining placebo recipients and 44% (7/16) of the acyclovir patients developed active HSV infections. Herpetic lesions occurred in two of three and two of seven of infected people in the respective groups. No adverse effects of the drug were observed. The results show that HSV infections in immunosuppressed renal allograft recipients can be safely prevented, deferred, and ameliorated by an initial period of prophylaxis with a low dose of oral acyclovir.
40名血清中含有抗单纯疱疹病毒（HSV）抗体的患者参与了一项随机、安慰剂对照、双盲研究，该研究旨在探讨口服低剂量阿昔洛韦作为肾移植后预防HSV复发感染的效果。在术后30天的用药期间，21名接受安慰剂治疗的患者中有14人，19名接受阿昔洛韦治疗的患者中有1人出现了HSV感染再激活。前者中有11人出现疱疹性损害，而后者没有。在使用阿昔洛韦进行预防期间，其对HSV主动感染的防护在统计学上具有高度显著性。在移植后30至90天未使用抗病毒药物期间，其余接受安慰剂治疗的患者中有60%（3/5），接受阿昔洛韦治疗的患者中有44%（7/16）出现了HSV主动感染。相应组中，感染人群里分别有三分之二和七分之二出现了疱疹性损害。未观察到该药物的不良反应。结果表明，通过初期口服低剂量阿昔洛韦进行预防，免疫抑制的肾移植受者中的HSV感染可得到安全预防、延缓和改善。
